OBJECTIVE: To compare the Quality of Life (QoL) indexes of received two different schemes of chemotherapy patients in advanced Breast cancer. METHODS: Patients were assigned to chemotherapy. Arm A: standard scheme CAF (23 pts.), and arm B: included docetaxel scheme TAD (23 pts.). The instrument for QoL assessment was FACT –Taxane (Functional Assessment of Cancer Therapy for patients with Taxane toxicity). The questionnaire consists from 43 questions, 27 of them are general questions and 16 are questions concerning toxicity reactions of patients. The patients should answer the questions of the questionnaire before the treatment, after 3-rd and 6-th cycles of chemotherapy. RESULTS: According received data toxicity reactions were more pointed for TAD scheme then for CAF scheme. The mediana of utility indexes was 57.6 and 51.0 respectively after the 6-th cycle for additional (specific for Taxane ) questions. But the general utility index for arm B was higher then for arm A, 112 and 109 respectively. CONCLUSION: In Russia the most limiting factors of docetaxel usage are related to cost and toxicity issues. In this study we receive reliable evidence that docetaxel toxicity doesn’t influence on general QoL of the patients. Also in spite of toxicity reactions the QoL of docetaxel treated patients was higher then standard scheme treated patients.